Thermo Fisher Scientific
The system, which will launch first in the EU and then the US and China, will be integrated into the company's existing Cobas Pro Integrated Solutions analyzer.
Thermo Fisher Scientific Clinical Research Business Delivers Strong Results in First Full Year
Premium
Acquired in December 2021, PPD delivered over 20 percent of Thermo Fisher's core organic revenue growth in the fourth quarter and contributed $1.90 billion in revenue.
Launched in Europe in 2018 and the US in 2020, the fully automated mass spec-based analyzer failed to gain market traction, in large part due to a limited assay menu.
Top Five Articles on 360Dx Last Week: Mobile Phlebotomy Company Fraud; Quest, Agilent Deal; and More
Last week, readers were most interested in a guilty plea by a mobile phlebotomy company alleged to have engaged in a $7.5 million scheme.
Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test
The firms will develop the NGS-based CDx for non-small cell lung cancer drug Tagrisso using the Oncomine Dx Express Test on the Genexus Dx System.